Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Evaluation of One Step Nucleic Acid Amplification for detection of lymph node metastases compared to histopathological ultrastaging in women with endometrial cancer: a protocol for a diagnostic accuracy study

J. Kostun, A. Mescalchin, M. Pešta, R. Slunečko, KM. Ismail, V. Smoligová, J. Presl

. 2025 ; 25 (1) : 12. [pub] 20250109

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu protokol klinické studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010299

BACKGROUND: This is a multicentre, European, prospective trial evaluating the diagnostic accuracy of One Step Nucleic Acid Amplification (OSNA) compared to sentinel lymph nodes histopathological ultrastaging in endometrial cancer patients. METHODS: Centres with expertise in sentinel lymph node mapping in endometrial cancer patients in Europe will be invited to participate in the study. Participating units will be trained on the correct usage of the OSNA RD-210 analyser and nucleic acid amplification reagent kit LYNOAMP CK19 E for rapid detection of metastatic nodal involvement, based on the cytokeratin 19 (CK19) mRNA detection. Endometrial cancer patients ≥ 18 years listed for surgical treatment with sentinel lymph node mapping, with no history of other types of cancer and who provide a valid written consent will be considered potentially eligible for the study. However, they will only be enrolled if a successful sentinel lymph node mapping is retrieved. Each node will be processed according to the study protocol and assessed by both OSNA and ultrastaging. DISCUSSION: The accuracy of OSNA (index test) will be assessed against sentinel lymph node histopathological ultrastaging (reference test). This European study has the potential to be the largest study on the use of OSNA in endometrial cancer to date. OSNA could represent a modern diagnostic alternative to sentinel lymph node ultrastaging with the added benefits of standardisation and fast results. TRIAL REGISTRATION: The study was registered in the German Clinical Trial Register - Nr. DRKS00021520, registration date 25th of May 2020, URL of the trial registry record: https://drks.de/search/en/trial/DRKS00021520 .

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010299
003      
CZ-PrNML
005      
20250429134956.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12905-025-03550-4 $2 doi
035    __
$a (PubMed)39780118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kostun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Evaluation of One Step Nucleic Acid Amplification for detection of lymph node metastases compared to histopathological ultrastaging in women with endometrial cancer: a protocol for a diagnostic accuracy study / $c J. Kostun, A. Mescalchin, M. Pešta, R. Slunečko, KM. Ismail, V. Smoligová, J. Presl
520    9_
$a BACKGROUND: This is a multicentre, European, prospective trial evaluating the diagnostic accuracy of One Step Nucleic Acid Amplification (OSNA) compared to sentinel lymph nodes histopathological ultrastaging in endometrial cancer patients. METHODS: Centres with expertise in sentinel lymph node mapping in endometrial cancer patients in Europe will be invited to participate in the study. Participating units will be trained on the correct usage of the OSNA RD-210 analyser and nucleic acid amplification reagent kit LYNOAMP CK19 E for rapid detection of metastatic nodal involvement, based on the cytokeratin 19 (CK19) mRNA detection. Endometrial cancer patients ≥ 18 years listed for surgical treatment with sentinel lymph node mapping, with no history of other types of cancer and who provide a valid written consent will be considered potentially eligible for the study. However, they will only be enrolled if a successful sentinel lymph node mapping is retrieved. Each node will be processed according to the study protocol and assessed by both OSNA and ultrastaging. DISCUSSION: The accuracy of OSNA (index test) will be assessed against sentinel lymph node histopathological ultrastaging (reference test). This European study has the potential to be the largest study on the use of OSNA in endometrial cancer to date. OSNA could represent a modern diagnostic alternative to sentinel lymph node ultrastaging with the added benefits of standardisation and fast results. TRIAL REGISTRATION: The study was registered in the German Clinical Trial Register - Nr. DRKS00021520, registration date 25th of May 2020, URL of the trial registry record: https://drks.de/search/en/trial/DRKS00021520 .
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory endometria $x patologie $x genetika $x diagnóza $7 D016889
650    _2
$a keratin-19 $x genetika $7 D053539
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    12
$a lymfatické metastázy $x diagnóza $x patologie $7 D008207
650    _2
$a staging nádorů $7 D009367
650    12
$a techniky amplifikace nukleových kyselin $x metody $7 D021141
650    _2
$a prospektivní studie $7 D011446
650    12
$a sentinelová uzlina $x patologie $7 D000071036
650    _2
$a biopsie sentinelové lymfatické uzliny $x metody $7 D021701
650    _2
$a multicentrické studie jako téma $7 D015337
651    _2
$a Evropa $7 D005060
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mescalchin, Alessandra $u Sysmex Europe, Bornbach 1, 22848, Norderstedt, Germany
700    1_
$a Pešta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Slunečko, Robert $u Sikl ́s Department of Pathology, University Hospital Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Ismail, Khaled M $u Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Smoligová, Vendula $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Presl, Jiri $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Pilsen, Czech Republic. preslj@fnplzen.cz
773    0_
$w MED00008209 $t BMC women's health $x 1472-6874 $g Roč. 25, č. 1 (2025), s. 12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39780118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134952 $b ABA008
999    __
$a ok $b bmc $g 2311575 $s 1247380
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 1 $d 12 $e 20250109 $i 1472-6874 $m BMC women's health $n BMC Womens Health $x MED00008209
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace